ClinicalTrials.Veeva

Menu

A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

Teva Pharmaceuticals logo

Teva Pharmaceuticals

Status

Completed

Conditions

Relapsing Remitting Multiple Sclerosis

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

Enrollment

30 patients

Sex

All

Ages

20 to 57 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participation & completion of the NC-100 Clinical Trial.
  • Able and willing to sign an Informed Consent.

Exclusion criteria

none

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems